Journal article icon

Journal article

A global cross-sectional survey on neonatal analgosedation: unveiling global trends and challenges through latent class analysis

Abstract:
Purpose
This study aims to analyze global prescribing patterns for analgosedation in neonates during four critical care scenarios. The research explores existing patterns, their association with geographic and sociodemographic index (SDI), and adherence to evidence-based practices.

Methods
Data from a 2024 global survey of 924 responses to 28 questions were analyzed, focusing on four items for their high variability: premedication in intubation (Q17), sedation in preterm (Q19) and full-term newborns (Q23), and perinatal asphyxia (Q26). Latent class analysis (LCA) classified neonatal intensive care unit (NICU) prescriptions into patterns, assigning participants to the most likely class. Demographic variables, including geographic region and SDI, were compared using chi-square tests to assess associations.

Results
Three distinct prescribing patterns emerged for each scenario. In premedication during intubation, Europe and North America predominantly used Class 1, adhering to guidelines with fentanyl, atropine, and muscle relaxants. In contrast, Class 2, standard in Asia and Latin America-Caribbean, primarily utilized fentanyl and midazolam, with rare use of atropine and muscle relaxants. For analgosedation in newborns, higher-SDI NICUs favored fentanyl, while lower-SDI NICUs preferred midazolam or morphine combinations. In perinatal asphyxia cases, fentanyl was the leading choice in Class 3, especially in Europe. Dexmedetomidine use was limited, primarily appearing in Class 1 NICUs.

Conclusion
The study highlights substantial regional variability in neonatal analgosedation, influenced by SDI and geography. Despite established guidelines, gaps in evidence-based implementation persist. These findings underscore the need for global standardization of neonatal care protocols and further research on the long-term safety of midazolam and dexmedetomidine.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1007/s00431-025-06074-z

Authors

More by this author
Role:
Author
ORCID:
0000-0002-7916-4571
More by this author
Role:
Author
ORCID:
0000-0002-4921-1437
More by this author
Role:
Author
ORCID:
0000-0001-6650-7881
More by this author
Role:
Author
ORCID:
0000-0003-3378-5038
More by this author
Role:
Author
ORCID:
0000-0002-8715-7419

Contributors

Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Role:
Contributor
ORCID:
0000-0001-6206-0576
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Role:
Contributor
ORCID:
0000-0002-7981-0836
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Role:
Contributor
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Role:
Contributor
ORCID:
0000-0001-9548-7162


More from this funder
Funder identifier:
https://ror.org/00wjc7c48
More from this funder
Funder identifier:
https://ror.org/00789fa95


Publisher:
Springer
Journal:
European Journal of Pediatrics More from this journal
Volume:
184
Issue:
4
Article number:
241
Publication date:
2025-03-12
Acceptance date:
2025-03-02
DOI:
EISSN:
1432-1076
ISSN:
0340-6199


Language:
English
Keywords:
Pubs id:
2118425
Local pid:
pubs:2118425
Deposit date:
2025-04-15
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP